Step 3: Personalized Treatment Planning Nicolie Vogt, FNP-C, Angela Elliott, APRN, and our experienced team create individualized treatment protocols based on your: Current hormone levels and test results Symptom severity and duration Medical history and contraindications Lifestyle factors and commitment to therapy Response goals and expectations Budget considerations We don't believe in one-size-fits-all hormone replacementyour treatment should be as unique as you are
And to read about Compass clinical trial results, go here
Do you offer private concierge IV therapy services
Fadini GP, Albiero M, Seeger F, Poncina N, Menegazzo L, Angelini A, Castellani C, Thiene G, Agostini C, Cappellari R, Boscaro E, Zeiher A, Dimmeler S, Avogaro A
Ipamorelin: synthetic pentapeptide PEPTIDE SEQUENCE CJC-1295 (no DAC): H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH 2 CHEMICAL STRUCTURE CJC-1295: Ipamorelin: CHEMICAL STRUCTURE CJC-1295 (no DAC): C 152 H 252 N 44 O 42 Ipamorelin: C 38 H 49 N 9 O 5 Mechanism of Action The CJC-1295 (no DAC) + ipamorelin peptide blend stimulates endogenous growth hormone (GH) release by simultaneously activating the growth hormone-releasing hormone receptor (GHRH-R) and the ghrelin/growth hormone secretagogue receptor (GHSR), resulting in synergistic, physiologically pulsatile GH secretion
